Priming of T cell responses 2

Published on November 30, 2017   19 min

Other Talks in the Series: Immunotherapy of Cancer

0:00
Hi, this is Victor Appay speaking from The National Institute of Health and Medical Research in France. In the second part of my talk, I will concentrate more on the relationship of T cell priming in the context of tumour micro-environment, and its application in the context of cancer immunotherapy and aging. Now in this fourth part,
0:20
I will discuss about T cell priming in the context of the tumour micro-environment.
0:29
It has been shown that upon injection in mice, naive cells can infiltrate directly tumours, and this has been associated with an improved survival of the mice bearing the tumours.
0:45
Interestingly, increasing evidence support that tumours can support the infiltration, activation, and effector differentiation of naive CD8 T cells. Indeed, the adoptive transfer of naive tumour-specific CD8 T cells, into tumour-bearing mice, has been associated with the accumulation of activated CD8 T cells in the tumours, the acquisition of effector function, and the presentation of antigen to these cells by cross-presenting antigen presenting cells. Also, the recruitment of naive T cell within tumours has been shown to be favoured by the presence of high endothelial venules or HEVs. HEVs have been identified in a range of human tumours, and usually their presence has been associated with the observation of CD8 T effector cells, B cells, Th1 cells within the tumours, and organised into so-called tertiary lymphoid structures or TLS.